FDA's New Plavix Black-Box Warning Could Trigger Surge in CYP2C19 Testing

In its black-box warning, FDA says that genetic tests "are available to assess CYP2C19 genotype to determine if a patient is a poor metabolizer."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.